TECKRO’S technology is being used to fight the coronavirus pandemic, bringing its technology to a number of drug trials being conducted to help find a treatment for Covid-19
Currently, six trials have begun, with 10 or 12 countries involved in Europe, the US and Asia. Each trial has about 20 to 30 research sites, with about 180 research sites involved, mainly across Europe
CEO, Gary Hughes said: “The Covid-19 outbreak has highlighted the limitations of how clinical trials are run. Distributing study protocols via paper or as a PDF in portals was never efficient, but the restrictions introduced due to the pandemic means that the old way is no longer viable.
“For example, monitors going out to research sites isn’t possible at all now. And Personal Protective Equipment (PPE) is hardly conducive to consulting a protocol in a binder or a desktop portal.
“So using our technology is the way to ensure clinical trials continue safely without disruption. We hope this will become the new normal moving forward.” he said.
Teckro is a Life Science Company which uses machine learning technology to improve clinical trials safety and efficiency.
“Teckro provides the digital infrastructure for doctors, scientists and drug companies working hard to design these trials. This way they can communicate in real-time, streamlining the process, meaning more efficiency, fewer errors and greater patient safety.
“They say that great technological progress is made during times of crisis and this is certainly true when it comes to clinical trials.
“The pandemic means that the industry has had to quickly adopt technology solutions in order to keep running – and the pressure to discover new treatments for Covid-19 means that time is of the essence.” he added.
Teckro has had huge interest since the pandemic swept the globe, as site staff can no longer travel around sites so are using Teckro‘s technology on their digital devices.
